Can I Stay on 5mg Mounjaro, or Do I Have to Keep Increasing?

Step 1: Understand what the titration schedule is actually for

Mounjaro is approved in the UK at six strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg, each delivered by a once-weekly injection. The 2.5mg starting dose exists for one reason, to let your system settle before the medicine does its main work. It is a tolerability measure. The 5mg step is where the therapeutic effect genuinely begins for most people, and the NHS tirzepatide guidance describes the full schedule as a stepwise approach, with each increase typically four weeks apart.

What the schedule does not say is that every patient must reach 15mg. The SmPC (the clinical reference document that governs how Mounjaro is prescribed) frames dose escalation around tolerability and response, not around a clock. That distinction matters. If your body is responding at 5mg and you are not experiencing side effects that a higher dose might resolve, there is no automatic clinical reason to push upward.

People often assume the higher the dose, the better the outcome. That is partly true at a population level (the largest average weight losses in the SURMOUNT trials came at higher doses) but averages hide a wide range. Some people achieve meaningful, sustained results at lower doses, and a prescriber who sees that pattern has every reason to keep you where you are working well. You can read more about what the 5mg pen does and who it suits if you want a fuller picture of this specific dose.

Step 2: Know the two things that actually drive a dose change

Clinicians generally weigh up two factors when deciding whether to increase a dose: how much weight you are losing and how well you are tolerating treatment. The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% body weight has been lost after six months at the highest tolerated dose, continuing should be reviewed. That framing (highest tolerated dose) is important. It implies that for some patients, a lower dose is the right ceiling.

If you are losing weight steadily and wondering whether staying on 5mg long-term is a realistic option for weight loss, even if that pace is slower than the trial averages you may have read about, a prescriber has good grounds to keep you here rather than increase if side effects are minimal. Conversely, if progress has stalled and you are tolerating 5mg without difficulty, moving to 7.5mg is the logical next step. The question is clinical, not arithmetic.

It is also worth knowing that gastrointestinal side effects (nausea, loose stools, burping, indigestion) tend to peak after a dose increase and ease off over a couple of weeks. If you are still managing these at 5mg, your prescriber may suggest waiting a little longer at this level before any change, which is itself a reason you might stay on 5mg for longer than the standard four-week window. If you are curious about whether 7.5mg could be the right long-term stopping point for you, the same principles apply one rung up.

Step 3: Have the conversation with your prescriber before your next pen

We hear this question often, and it usually comes from a place of genuine uncertainty rather than wanting to game the process. You have found something that seems to be working, and you do not want to disrupt it by increasing the dose. That instinct is reasonable, and a good prescriber will take it seriously.

At nume, every repeat order is reviewed by a real clinician before it is approved. A named prescriber reads your progress update (your weight, how you have been feeling, any side effects) and makes an active decision about your next pen. That means if you want to stay at 5mg, you raise it at that point. The prescriber can agree, ask a few follow-up questions, or explain why they recommend a different course. What they will not do is bump your dose automatically without looking at your situation.

If you are weighing up costs as part of this decision, it is worth knowing that treatment pricing varies by dose, you can see the full breakdown on the treatment page. Staying at a lower dose is not a shortcut, but it is a legitimate outcome if the clinical picture supports it. Before that conversation with your prescriber, it can also help to read through the common questions our clinical team fields so you go in with the right information.

What the evidence tells us about lower-dose outcomes

The headline figures from the SURMOUNT-1 trial (around 20% average weight loss at 15mg over 72 weeks) are widely quoted, and rightly so. But the trial also showed meaningful weight reduction at lower maintenance doses. Participants did not universally need the maximum dose to see clinically significant results. This is one reason the licensed schedule allows prescribers to find the lowest effective dose for each individual, rather than pushing everyone to 15mg.

It is also true that the 5mg dose in the SURMOUNT programme was primarily a titration step rather than a studied maintenance dose in isolation, so direct long-term data at exactly 5mg is limited. Your prescriber will factor this in. What the evidence does support clearly is that results depend on sustained use alongside a reduced-calorie diet and increased activity, at whatever dose the prescriber decides is right. If you are considering how Mounjaro fits into your broader weight-loss approach, the weight-loss overview sets out the full picture.

For anyone wondering about the very first step down, there is also useful context on whether it is ever appropriate to remain on the 2.5mg starter dose longer term, the considerations are similar, though the clinical reasoning differs slightly at that starter dose.